Societal CDMO (Nasdaq:SCTL) - 주가, 뉴스 및 분석

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

SCTL 주식 개요

Societal CDMO, Inc., a contract development and manufacturing organization, engages in the research and development, manufacturing, and packaging for various therapeutic dosage forms primarily in the small molecules in the United States and internationally.

회사 소개

SCTL 기본 분석
눈송이 점수
가치 평가	3/6
미래 성장	1/6
과거 실적	0/6
재무 상태	3/6
배당금	0/6

보상

수익은 연간 8.27% 증가할 것으로 예상됩니다.

동종업계 및 업계 대비 좋은 가치로 거래

위험 분석

최근 3개월간 주가 변동폭 심해

지난 5년간 매년 수익이 31.7% 씩 감소했습니다.

현재 수익성이 없으며 향후 3년 동안 수익을 낼 것으로 예상되지 않습니다.

cash runway 경력이 1년 미만입니다.

+ 1 더 많은 위험

Societal CDMO, Inc. 경쟁사

Journey Medical

NasdaqCM:DERM

US$118.6m

Assertio Holdings

NasdaqCM:ASRT

US$112.5m

Jushi Holdings

OTCPK:JUSH.F

US$104.2m

Cannabist Company Holdings

OTCPK:CBST.F

US$106.4m

가격 내역 및 성능

다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 Societal CDMO
과거 주가
현재 주가	US$1.10
52주 최고치	US$1.28
52주 최저치	US$0.26
베타	1.52
11개월 변경	1.85%
3개월 변경 사항	181.33%
1년 변경 사항	4.76%
33년 변화	-65.52%
5년 변화	-86.89%
IPO 이후 변화	-86.75%

최근 뉴스 및 업데이트

Recent updates

Societal CDMO, Inc.'s (NASDAQ:SCTL) Price Is Right But Growth Is Lacking After Shares Rocket 38%

Feb 10

Is There An Opportunity With Societal CDMO, Inc.'s (NASDAQ:SCTL) 46% Undervaluation?

Feb 02

These 4 Measures Indicate That Societal CDMO (NASDAQ:SCTL) Is Using Debt Extensively

Apr 29

Is Recro Pharma (NASDAQ:REPH) A Risky Investment?

Jan 06

Recro Pharma jumps 15% on Q1 result estimates beat

May 07

Would Shareholders Who Purchased Recro Pharma's (NASDAQ:REPH) Stock Year Be Happy With The Share price Today?

Feb 15

주주 수익률

	SCTL	US Pharmaceuticals	US 마켓
7D	0%	-2.6%	0.7%
1Y	4.8%	20.9%	32.3%

수익률 대 산업: SCTL 지난 1년 동안 17.4 %를 반환한 US Pharmaceuticals 업계보다 저조한 성과를 냈습니다.

수익률 대 시장: SCTL 지난 1년 동안 23.3 %를 반환한 US 시장보다 저조한 성과를 냈습니다.

가격 변동성

Is SCTL's price volatile compared to industry and market?
SCTL volatility
SCTL Average Weekly Movement	39.2%
Pharmaceuticals Industry Average Movement	9.7%
Market Average Movement	6.4%
10% most volatile stocks in US Market	14.8%
10% least volatile stocks in US Market	3.2%

안정적인 주가: SCTL 의 주가는 지난 3개월 동안 변동성이 심했습니다.

시간에 따른 변동성: SCTL 의 주간 변동성은 지난 1년 동안 23% 에서 39% 로 증가했습니다.

회사 소개

설립	직원	CEO	웹사이트
2007	258	J. Enloe	www.societalcdmo.com

Societal CDMO, Inc. 기본 사항 요약

Societal CDMO 의 수익과 매출은 시가총액과 어떻게 비교하나요?
SCTL 기본 통계
시가총액	US$116.26m
수익(TTM)	-US$13.27m
수익(TTM)	US$94.64m

1.2x

P/S 비율

-8.8x

P/E 비율

SCTL 주가가 과대평가되어 있나요?

공정 가치 및 가치 분석 보기

수익 및 수익

최신 수익 보고서의 주요 수익성 통계(TTM)
SCTL 손익 계산서(TTM)
수익	US$94.64m
수익 비용	US$76.50m
총 이익	US$18.14m
기타 비용	US$31.41m
수익	-US$13.27m

최근 보고된 수익

Dec 31, 2023

다음 수익 날짜

n/a

주당 순이익(EPS)	-0.13
총 마진	19.17%
순이익 마진	-14.03%
부채/자본 비율	63.2%

SCTL 의 장기적인 성과는 어땠나요?

과거 실적 및 비교 보기

This company has been acquired

SCTL 주식 개요

보상

위험 분석

Societal CDMO, Inc. 경쟁사

NasdaqCM:DERM

US$118.6m

NasdaqCM:ASRT

US$112.5m

OTCPK:JUSH.F

US$104.2m

OTCPK:CBST.F

US$106.4m

가격 내역 및 성능

최근 뉴스 및 업데이트

Societal CDMO, Inc. Files Form 15

Societal CDMO, Inc.(NasdaqCM:SCTL) dropped from NASDAQ Composite Index

Societal CDMO's Common Stock to be Delisted from the Nasdaq Capital Market as a Result of the Merger with CoreRx

Full year 2023 earnings: EPS and revenues exceed analyst expectations

CoreRx, Inc. entered into a definitive agreement to acquire Societal CDMO, Inc. (NasdaqCM:SCTL) from First Light Asset Management, LLC and Others for approximately $120 million.

New major risk - Share price stability

Recent updates

Societal CDMO, Inc. Files Form 15

Societal CDMO, Inc.(NasdaqCM:SCTL) dropped from NASDAQ Composite Index

Societal CDMO's Common Stock to be Delisted from the Nasdaq Capital Market as a Result of the Merger with CoreRx

Full year 2023 earnings: EPS and revenues exceed analyst expectations

CoreRx, Inc. entered into a definitive agreement to acquire Societal CDMO, Inc. (NasdaqCM:SCTL) from First Light Asset Management, LLC and Others for approximately $120 million.

New major risk - Share price stability

Now 29% overvalued after recent price rise

Societal CDMO, Inc.'s (NASDAQ:SCTL) Price Is Right But Growth Is Lacking After Shares Rocket 38%

Is There An Opportunity With Societal CDMO, Inc.'s (NASDAQ:SCTL) 46% Undervaluation?

Is Societal CDMO (NASDAQ:SCTL) Weighed On By Its Debt Load?

Price target decreased by 14% to US$1.86

High number of new directors

Nasdaq Grants Societal CDMO an Additional 180 Calendar Days to Regain Compliance with Minimum Bid Price Requirement

Societal CDMO, Inc. Resets Earnings Guidance for the Year 2023

Societal CDMO, Inc. to Report Q3, 2023 Results on Nov 08, 2023

Societal CDMO, Inc. Reduces its Workforce by 26 Positions Across All Aspects of the Business

High number of new directors

Price target decreased by 18% to US$2.30

Societal CDMO, Inc. has completed a Follow-on Equity Offering.

Societal Cdmo Announces Appointment of Matt Arens to Board of Directors

Consensus EPS estimates fall by 18%

New major risk - Shareholder dilution

Second quarter 2023 earnings: EPS misses analyst expectations

Societal CDMO, Inc. to Report Q2, 2023 Results on Aug 09, 2023

New minor risk - Share price stability

Does Societal CDMO (NASDAQ:SCTL) Have A Healthy Balance Sheet?

Societal CDMO Receives Deficiency Letter from Nasdaq Regarding Minimum Bid Price Requirement

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Societal CDMO, Inc. Reaffirms 2023 Financial Guidance

Societal CDMO, Inc. to Report Q1, 2023 Results on May 10, 2023

Forecast to breakeven in 2025

Price target decreased by 13% to US$3.64

Full year 2022 earnings: EPS misses analyst expectations

Price target increased by 19% to US$5.00

Consensus EPS estimates fall by 16%

Societal CDMO, Inc. has completed a Follow-on Equity Offering in the amount of $30.625911 million.

Societal CDMO, Inc. has completed a Follow-on Equity Offering in the amount of $30.625911 million.

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Societal CDMO, Inc. Provides Earnings Guidance for the Full Year 2022

Societal CDMO, Inc. to Report Q3, 2022 Results on Nov 09, 2022

Societal CDMO signs two CDMO service agreements

Societal CDMO, Inc. Appoints Elena Cant as Board of Directors

Societal stock soars 20% on signing 2 manufacturing contracts

Societal CDMO estimates to receive up to $50M on real estates' sales

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Societal CDMO, Inc. Provides Earnings Guidance for the Full Year Ending December 31, 2022

Societal CDMO, Inc. to Report Q2, 2022 Results on Aug 10, 2022

Societal CDMO, Lannett amend license and supply deal

Railroad Ranch Capital Engages in Discussions with Societal CDMO

Societal Cdmo Unveils 20/80 Second Source Technical Transfer Service Model, Offering Cost and Time Savings for Pharmaceutical Manufacturing

Consensus forecasts updated

Societal CDMO, Inc. Provides Earnings Guidance for the Year Ending December 31, 2022

Societal CDMO, Inc. to Report Q1, 2022 Results on May 11, 2022

These 4 Measures Indicate That Societal CDMO (NASDAQ:SCTL) Is Using Debt Extensively

Price target decreased to US$5.00

Societal CDMO, Inc., Annual General Meeting, May 18, 2022

Consensus forecasts updated

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind